Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone (AWAOMI2)
A Multicentric Open-label Randomized Controlled Study for Evaluating the Improvement of Endothelial Function in Stage II Peripheral Arterial Obstructive Disease Patients Treated With Sulodexide + Conventional Treatment {CT] Vs CT Alone
Sponsor: Alfa Wassermann Tunisia
A PHASE3 clinical study on Peripheral Arterial Obstructive Disease, this trial is ongoing. The trial is conducted by Alfa Wassermann Tunisia and has accumulated 10 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Aug 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
Status: Not Yet Recruiting → Active Not Recruiting
-
Feb 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alfa Wassermann Tunisia
- Poseidon CRO
For direct contact, visit the study record on ClinicalTrials.gov .